Ketoanalogues For Kidney Diseases Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 231.08 Million |
| Market Size (2029) | USD 338.47 Million |
| CAGR (2024 - 2029) | 7.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Ketoanalogues For Kidney Diseases Market Analysis
The Ketoanalogues For Kidney Diseases Market size is estimated at USD 231.08 million in 2024, and is expected to reach USD 338.47 million by 2029, growing at a CAGR of 7.90% during the forecast period (2024-2029).
The rising prevalence of various kidney diseases around the world, such as chronic kidney disease (CKD) and diabetic kidney disease, is a major factor driving the market growth as it is expected to boost the usage of ketoanalogues for treatment. For instance, according to the data updated by Kidney Research UK in June 2023, it was estimated that approximately 3.25 million people were living with chronic kidney disease (CKD) stages 3-5 in the United Kingdom in 2022. A further 3.9 million people were estimated to have CKD stages 1-2, together reaching a total of 7.2 million in 2022, which was more than 10% of the entire population. Hence, the growing burden of CKD is expected to drive the adoption of ketoanalogues, thereby boosting the market's growth.
Moreover, according to an article published by the Journal of Kidney and Dialysis in July 2023, approximately 20%–50% of patients with type 2 diabetes mellitus would ultimately develop diabetic kidney disease (DKD). On a global basis, DKD is expected to be the leading cause of chronic kidney disease and end-stage kidney disease, accounting for 50% of DKD cases. Thus, the high prevalence of such diseases is also driving the market growth.
In addition, the increase in clinical trial activities to check the efficacy of ketoanalogues in various kidney diseases is also positively affecting the growth of the market. For instance, according to the data updated by ClinicalTrials.gov in August 2023, Hospices Civils de Lyon of France is expected to conduct a clinical trial to check the effect of ketoanalogue supplementation in uremic toxins production in patients suffering from CKD. Thus, owing to such clinical trials, the market studied is expected to grow significantly over the forecast period.
Therefore, owing to the factors mentioned above, the market studied is anticipated to grow over the analysis period. However, the lack of knowledge about ketoanalogues is likely to impede the market growth.
Ketoanalogues For Kidney Diseases Market Trends
The Chronic Kidney Disease Segment is Expected to Witness Significant Growth Over the Forecast Period
Chronic kidney disease (CKD) is a severe condition in which the kidneys are damaged and cannot function like the healthy kidney. Factors such as the rising prevalence of CKD around the world and the rising usage of ketoanalogues for treatment are expected to boost the growth of the segment during the forecast period.
For instance, according to an article published by the Journal of Renal Failure in January 2023, China is said to have a high prevalence of CKD. CKD is rising in rank among the leading diseases with a high burden worldwide due to factors such as aging and the risk factors associated with this health condition, including diabetes and hypertension. Thus, the high burden of CKD across various countries is also expected to boost the adoption of ketoanalogues, driving segment growth.
Moreover, the high prevalence of CKD among older people is also expected to boost the segment growth. According to the data updated by the National Health Service (NHS) of the United Kingdom in August 2022, chronic kidney disease (CKD) is considered a very common condition in the country, often associated with getting older, and can affect anyone. It has also been observed that CKD can get worse over time, and eventually, the kidneys may stop working altogether, leading to kidney failure. Thus, such a high burden and persistent risk of CKD among the older population is expected to drive segment growth.
Therefore, the chronic kidney disease segment is expected to witness significant growth over the forecast period due to the abovementioned factors, such as the high prevalence of CKD and the increasing geriatric population.
North America is Expected to Hold a Significant Share of the Market Over the Forecast Period
North America is expected to hold a significant share of the market owing to factors such as the easy availability of newer products and the increase in the adoption of ketoanalogues for kidney diseases. Moreover, the rising prevalence of chronic kidney diseases and the increasing geriatric population in the region are also among the key factors contributing to the market growth in North America.
For instance, according to the data published by the Kidney Foundation of Canada in 2022, it was estimated that 1 in 10 Canadians had kidney disease in 2022, which was around 4 million people. The leading cause of kidney failure in the country is estimated to be diabetes, and the number of people living with end‐stage kidney disease has grown by 31% in the last 10 years, and 54% of new patients are over the age of 65. The source also stated that more than 52,000 Canadians were treated for kidney failure in 2022. Thus, the high prevalence of kidney diseases in the country is expected to boost segment growth.
Moreover, according to the data updated by the Centers for Disease Control and Prevention (CDC) in May 2024, more than 1 in 7 adults in the United States, about 35.5 million people, or 14% of the total population, were estimated to be diagnosed with CKD in 2023. The source also stated that CKD was more common in people aged 65 years or older (34%) than in people aged 45-64 years (12%) or 18-44 years (6%). Thus, the high burden of CKD in the country is expected to lead to an increased usage of ketoanalogues, thus driving the market growth.
Therefore, owing to the abovementioned factors, the market studied is anticipated to flourish in North America.
Ketoanalogues For Kidney Diseases Industry Overview
The ketoanalogues for kidney diseases market is fragmented due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some of the key market players include Fresenius Kabi AG, RPG Life Sciences Limited, Alniche Life Sciences Pvt. Ltd, La Renon Healthcare Pvt. Ltd, and Steadfast Medishield Private Limited.
Ketoanalogues For Kidney Diseases Market Leaders
-
Fresenius Kabi AG
-
RPG Life Sciences Limited
-
Alniche Life Sciences Pvt. Ltd.
-
La Renon Healthcare Pvt Ltd
-
Steadfast Medishield Private Limited
*Disclaimer: Major Players sorted in no particular order
Ketoanalogues For Kidney Diseases Market News
- June 2024: The Mansoura University of Egypt started a randomized clinical trial to observe the effect of ketoanalogue supplementation and exercises in hemodialysis patients.
- January 2023: The Military Institute of Medicine of Poland initiated a clinical trial to evaluate the effectiveness and safety of ketoanalogues of essential amino acids for preventing protein-energy wasting in nephrotic syndrome.
Ketoanalogues For Kidney Diseases Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Kidney Diseases
4.2.2 Increasing Adoption of Ketoanalogues In Dialysis Patients
4.3 Market Restraints
4.3.1 Lack of Knowledge About Ketoanalogues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Application
5.1.1 Chronic Kidney Disease
5.1.2 Renal Failure
5.1.3 Other Applications
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Retail Pharmacy
5.2.3 Online Distribution Channels
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East and Africa
5.3.5 South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Fresenius Kabi AG
6.1.2 RPG Life Sciences Limited
6.1.3 Alniche Life Sciences Pvt. Ltd
6.1.4 La Renon Healthcare Pvt. Ltd
6.1.5 Steadfast Medishield Private Limited
6.1.6 Centaur Pharmaceuticals
6.1.7 Genix Lifescience Pvt. Ltd
6.1.8 United Laboratories
6.1.9 Yaxon Biocare Pvt. Ltd
6.1.10 Biokindle Lifesciences Pvt. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Ketoanalogues For Kidney Diseases Industry Segmentation
As per the scope of the report, ketoanalogues are used for the treatment of various kidney diseases, and they work by preventing the unnecessary increase in urea levels in the blood due to the intake of non-essential amino acids.
The ketoanalogues for kidney diseases market is segmented by application (chronic kidney disease, renal failure, and other applications), distribution channel (hospital pharmacy, retail pharmacy, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market sizes and forecasts in terms of value (USD) for the above segments.
| By Application | |
| Chronic Kidney Disease | |
| Renal Failure | |
| Other Applications |
| By Distribution Channel | |
| Hospital Pharmacy | |
| Retail Pharmacy | |
| Online Distribution Channels |
| Geography | |
| North America | |
| Europe | |
| Asia-Pacific | |
| Middle East and Africa | |
| South America |
Ketoanalogues For Kidney Diseases Market Research Faqs
How big is the Ketoanalogues For Kidney Diseases Market?
The Ketoanalogues For Kidney Diseases Market size is expected to reach USD 231.08 million in 2024 and grow at a CAGR of 7.90% to reach USD 338.47 million by 2029.
What is the current Ketoanalogues For Kidney Diseases Market size?
In 2024, the Ketoanalogues For Kidney Diseases Market size is expected to reach USD 231.08 million.
Who are the key players in Ketoanalogues For Kidney Diseases Market?
Fresenius Kabi AG, RPG Life Sciences Limited, Alniche Life Sciences Pvt. Ltd., La Renon Healthcare Pvt Ltd and Steadfast Medishield Private Limited are the major companies operating in the Ketoanalogues For Kidney Diseases Market.
Which is the fastest growing region in Ketoanalogues For Kidney Diseases Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Ketoanalogues For Kidney Diseases Market?
In 2024, the North America accounts for the largest market share in Ketoanalogues For Kidney Diseases Market.
What years does this Ketoanalogues For Kidney Diseases Market cover, and what was the market size in 2023?
In 2023, the Ketoanalogues For Kidney Diseases Market size was estimated at USD 212.82 million. The report covers the Ketoanalogues For Kidney Diseases Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Ketoanalogues For Kidney Diseases Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Ketoanalogues For Kidney Diseases Industry Report
Statistics for the 2024 Ketoanalogues For Kidney Diseases market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Ketoanalogues For Kidney Diseases analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
